Amphastar Pharmaceuticals (AMPH) Net Margin (2013 - 2026)

Amphastar Pharmaceuticals' Net Margin history runs 14 years deep, the most recent figure standing at 3.75% for Q1 2026.

• In Q1 2026, Net Margin fell 1108.0% year-over-year to 3.75%; the TTM figure through Mar 2026 stood at 6.9% (down 2703.0% YoY), while the FY2025 annual figure was 4.29%, down 2690.0% from the prior year.
• Net Margin was 3.75% for Q1 2026 at Amphastar Pharmaceuticals, up from 57.08% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 27.48% in Q3 2023 to a low of 57.08% in Q4 2025.
• Historically, Net Margin has averaged 13.99% across 5 years, with a median of 19.15% in 2023.
• The sharpest annual moves came in 2022 and 2025: Net Margin jumped 1689 bps in 2022, then sank 8034 bps in 2025.
• A 5-year view of Net Margin shows it stood at 25.16% in 2022, then dropped by 18 bps to 20.59% in 2023, then rose by 13 bps to 23.26% in 2024, then plunged by 345 bps to 57.08% in 2025, then surged by 107 bps to 3.75% in 2026.
• The last three Net Margin figures came in at 3.75% (Q1 2026), 57.08% (Q4 2025), and 9.04% (Q3 2025), per Business Quant data.